lung non-small cell carcinoma (Cancer)
Information
- Disease name
- lung non-small cell carcinoma
- Disease ID
- DOID:3908
- Description
- "A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma." [url:http\://en.wikipedia.org/wiki/Non-small-cell_lung_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04013542 | Active, not recruiting | Phase 1 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | September 13, 2019 | December 31, 2024 |
| NCT03707938 | Active, not recruiting | Phase 1 | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | December 18, 2018 | January 28, 2026 |
| NCT03410043 | Active, not recruiting | Phase 2 | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | January 17, 2018 | June 1, 2025 |
| NCT04694846 | Active, not recruiting | N/A | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | August 19, 2020 | August 16, 2024 |
| NCT03939481 | Active, not recruiting | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | May 14, 2019 | February 28, 2026 | |
| NCT03546361 | Active, not recruiting | Phase 1 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | July 8, 2019 | January 11, 2025 |
| NCT04032418 | Active, not recruiting | Phase 2 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | August 13, 2020 | January 5, 2025 |
| NCT02983578 | Active, not recruiting | Phase 2 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | March 2, 2017 | April 30, 2025 |
| NCT03637816 | Active, not recruiting | Phase 2/Phase 3 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | November 27, 2018 | December 31, 2024 |
| NCT04946279 | Active, not recruiting | N/A | Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer | August 7, 2020 | June 30, 2025 |
| NCT05740501 | Completed | Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer | April 26, 2017 | January 3, 2020 | |
| NCT05304793 | Completed | N/A | Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer | July 1, 2020 | July 16, 2021 |
| NCT03944265 | Completed | N/A | Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer | February 8, 2019 | December 31, 2020 |
| NCT06418204 | Not yet recruiting | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | August 2024 | August 2028 | |
| NCT06116682 | Not yet recruiting | Phase 2 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | July 16, 2024 | May 2029 |
| NCT06427369 | Not yet recruiting | Phase 1 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | September 1, 2024 | September 1, 2027 |
| NCT06438588 | Recruiting | N/A | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial | March 6, 2024 | March 15, 2027 |
| NCT03391869 | Recruiting | Phase 3 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | December 29, 2017 | December 31, 2025 |
| NCT03634241 | Recruiting | Phase 2 | Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | November 13, 2018 | July 31, 2025 |
| NCT03819296 | Recruiting | Phase 1/Phase 2 | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | February 21, 2021 | October 31, 2025 |
| NCT03948100 | Recruiting | N/A | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | December 20, 2018 | April 30, 2025 |
| NCT04073745 | Recruiting | Phase 1 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | November 6, 2019 | November 1, 2025 |
| NCT04214262 | Recruiting | Phase 3 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | August 13, 2020 | May 1, 2028 |
| NCT04267848 | Recruiting | Phase 3 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial | June 16, 2020 | December 15, 2024 |
| NCT04298606 | Recruiting | Early Phase 1 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | November 22, 2021 | November 22, 2024 |
| NCT04314401 | Recruiting | National Cancer Institute "Cancer Moonshot Biobank" | November 11, 2020 | September 16, 2025 | |
| NCT04407247 | Recruiting | Phase 1/Phase 2 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | July 9, 2020 | December 31, 2024 |
| NCT04428905 | Recruiting | N/A | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | July 11, 2020 | March 31, 2025 |
| NCT04430725 | Recruiting | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study | August 7, 2019 | January 1, 2026 | |
| NCT04625647 | Recruiting | Phase 2 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | April 16, 2021 | December 31, 2027 |
| NCT05416983 | Recruiting | Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer | February 17, 2022 | April 2026 | |
| NCT05443971 | Recruiting | Phase 2 | Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen | July 3, 2023 | June 30, 2025 |
| NCT05493566 | Recruiting | Early Phase 1 | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | November 1, 2022 | January 7, 2026 |
| NCT05502523 | Recruiting | N/A | The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer | August 31, 2022 | January 1, 2029 |
| NCT05672108 | Recruiting | Phase 2 | Transarterial Chemoembolization for the Treatment of Lung Cancer | May 12, 2023 | October 31, 2024 |
| NCT05717998 | Recruiting | Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy | April 2, 2021 | December 31, 2025 | |
| NCT05801406 | Recruiting | From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection. | March 24, 2023 | September 30, 2024 | |
| NCT05802186 | Recruiting | N/A | Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study | November 20, 2023 | March 1, 2026 |
| NCT05830058 | Recruiting | Phase 2 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | November 29, 2023 | January 6, 2026 |
| NCT06014827 | Recruiting | Phase 2 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma | June 25, 2024 | July 11, 2026 |
| NCT06122064 | Recruiting | N/A | A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer | November 20, 2023 | October 31, 2026 |
| NCT06139627 | Recruiting | N/A | Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy | June 16, 2024 | July 19, 2026 |
| NCT06225427 | Recruiting | Phase 1 | Gilteritinib for the Treatment of ALK NSCLC | May 2024 | March 2027 |
| NCT06265285 | Recruiting | Phase 2 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | March 13, 2024 | December 31, 2026 |
| NCT02955290 | Recruiting | Phase 1/Phase 2 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | December 22, 2016 | December 9, 2027 |
| NCT04913311 | Recruiting | Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer | January 21, 2021 | February 2, 2027 | |
| NCT04929041 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | October 7, 2022 | December 31, 2027 |
| NCT05242965 | Recruiting | Phase 2 | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer | March 24, 2023 | December 31, 2026 |
| NCT05292521 | Recruiting | N/A | Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer | December 21, 2023 | January 15, 2025 |
| NCT05340309 | Recruiting | Phase 2 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | December 7, 2022 | December 7, 2026 |
| NCT05364645 | Recruiting | Phase 2 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | July 25, 2022 | May 1, 2029 |
| NCT05501665 | Suspended | Phase 1/Phase 2 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | May 9, 2023 | February 1, 2027 |
| NCT04836429 | Suspended | Phase 1 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | March 10, 2022 | March 17, 2025 |
| NCT03824327 | Suspended | Phase 1 | Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases | February 7, 2019 | December 31, 2024 |
| NCT04348292 | Terminated | Phase 1 | Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | January 22, 2021 | November 4, 2022 |
| NCT04705025 | Terminated | N/A | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer | April 8, 2021 | March 30, 2023 |
| NCT04005144 | Terminated | Phase 1 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | February 25, 2020 | October 1, 2022 |
| NCT03707925 | Terminated | N/A | Bronchoscopic Laser Ablation of Peripheral Lung Tumors | September 18, 2018 | January 20, 2022 |
| NCT05106374 | Unknown status | Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer | September 4, 2018 | December 31, 2023 | |
| NCT05022394 | Withdrawn | Phase 1/Phase 2 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | February 18, 2021 | February 18, 2021 |
| NCT04262869 | Withdrawn | Phase 2 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | March 27, 2020 | October 18, 2021 |
| NCT04061590 | Withdrawn | Phase 2 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | May 29, 2020 | August 31, 2023 |
| NCT04085081 | Withdrawn | N/A | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers | May 15, 2021 | November 1, 2022 |
| NCT05412875 | Withdrawn | N/A | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | January 1, 2024 | January 31, 2024 |
| NCT04989283 | Withdrawn | Phase 2 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | September 9, 2021 | May 10, 2031 |
| NCT04987281 | Withdrawn | Phase 2 | Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study | January 26, 2022 | December 27, 2023 |
- Disase is a (Disease Ontology)
- DOID:3905
- Cross Reference ID (Disease Ontology)
- EFO:0003060
- Cross Reference ID (Disease Ontology)
- KEGG:05223
- Cross Reference ID (Disease Ontology)
- MESH:D002289
- Cross Reference ID (Disease Ontology)
- NCI:C2926
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254637007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007131
- Exact Synonym (Disease Ontology)
- Non-small cell lung cancer
- Exact Synonym (Disease Ontology)
- non-small cell lung carcinoma
- Exact Synonym (Disease Ontology)
- NSCLC